Initial Results of Secukinumab Drug Survival in Patients with Psoriasis: A Multicentre Daily Practice Cohort Study
Interleukin 17-antagonist secukinumab demonstrated high efficacy for treatment of psoriasis in randomized controlled trials. However, performance in daily practice may differ from trials. Drug survival is a comprehensive outcome covering effectiveness and safety, suitable for analyses of daily pract...
Main Authors: | Juul M.P.A. van den Reek, Lieke J. van Vugt, Martijn B.A. van Doorn, Gayle E. van der Kraaij, Wim J.A. de Kort, Georges P.H. Lucker, Barbara Horvath, M. David Njoo, H. Jorn Bovenschen, Paul M. Ossenkoppele, Marjolein S. De Bruin-Weller, Marjan de Groot, Roland Mommers, Ruud L.M.A. Prevoo, Peter C.M. van de Kerkhof, Phyllis I. Spuls, Wietske Kievit, Elke M.G.J. de Jong |
---|---|
Format: | Article |
Language: | English |
Published: |
Society for Publication of Acta Dermato-Venereologica
2018-04-01
|
Series: | Acta Dermato-Venereologica |
Subjects: | |
Online Access: |
https://www.medicaljournals.se/acta/content/html/10.2340/00015555-2900
|
Similar Items
-
Secukinumab: supervivencia en práctica clínica real
by: R. Ruiz-Villaverde, et al.
Published: (2021-04-01) -
Treatment challenges in the management of moderate-to-severe plaque psoriasis – role of secukinumab
by: Malakouti M, et al.
Published: (2016-10-01) -
Secukinumab for rheumatology: development and its potential place in therapy
by: Koenders MI, et al.
Published: (2016-06-01) -
Apremilast coadministered with secukinumab for safe and effective control of psoriasis with resultant reduction of maintenance dose of the biologic
by: Abhishek De, et al.
Published: (2019-01-01) -
Clinical utility of secukinumab in moderate-to-severe scalp psoriasis: evidence to date
by: Kivelevitch D, et al.
Published: (2019-04-01)